Menkes Disease

What is Menkes Disease?

Menkes disease is a rare genetic disorder that affects how your body processes and uses copper. Copper is an essential mineral that plays a critical role in brain development, immune function, and the health of your connective tissue, hair, and blood vessels. When someone has Menkes disease, their body cannot properly absorb and distribute copper from the digestive system to the rest of the body.

This condition is caused by mutations in a specific gene that controls copper transport proteins. Without these proteins working correctly, copper gets trapped in certain tissues while other parts of the body experience severe copper deficiency. The brain, bones, and arteries suffer the most from this imbalance.

Menkes disease primarily affects males and typically shows symptoms in the first few months of life. Early diagnosis and treatment are critical for managing symptoms and improving quality of life. The condition is named after Dr. John Menkes, who first described it in 1962.

Ceruloplasmin

Reveal copper metabolism issues effortlessly
Diagnose Wilson's disease with precision
Clarify unexplained neurological symptoms quickly

^$56

Copper, Serum or Plasma

Pinpoint the cause of unexplained fatigue
Reveal hidden nutritional imbalances
Clarify the source of persistent health issues

^$70

Copper, Random Urine

Pinpoint copper imbalances affecting your energy
Reveal hidden causes of unexplained symptoms
Clarify potential issues with nutrient absorption

^$372

Symptoms

Kinky, sparse, or brittle hair that breaks easily
Weak muscle tone and poor muscle development
Seizures that may begin in early infancy
Failure to gain weight or grow at expected rates
Decreased body temperature and difficulty regulating temperature
Developmental delays in motor skills and cognitive abilities
Loose or sagging skin with a pale appearance
Feeding difficulties and trouble swallowing
Weak and fragile bones that fracture easily
Unusual facial features including chubby cheeks and a flat nasal bridge

Most infants with Menkes disease appear healthy at birth. Symptoms typically emerge between 6 weeks and 3 months of age as copper deficiency worsens.

Causes and risk factors

Menkes disease is caused by mutations in the ATP7A gene located on the X chromosome. This gene provides instructions for making a protein that transports copper throughout the body. When the gene is mutated, the copper transport protein does not work properly. Copper builds up in the small intestine and kidneys but cannot reach the brain, liver, and other organs that need it.

Because the condition is X-linked recessive, it primarily affects males. Females can be carriers of the mutated gene but typically do not show symptoms. A mother who carries one copy of the mutated gene has a 50% chance of passing it to each child. Sons who inherit the mutation will develop the disease, while daughters who inherit it will become carriers. In some cases, the genetic mutation occurs spontaneously with no family history.

How it's diagnosed

Diagnosis of Menkes disease typically begins with a physical examination and review of symptoms, particularly the characteristic kinky hair and developmental delays. Blood tests measuring copper and ceruloplasmin levels are essential diagnostic tools. Ceruloplasmin is a protein that carries copper in the bloodstream. Low levels of both copper and ceruloplasmin strongly suggest Menkes disease.

Rite Aid offers blood testing for copper and ceruloplasmin as part of our add-on testing options. These tests can help identify abnormal copper metabolism that may indicate Menkes disease. Genetic testing to identify mutations in the ATP7A gene confirms the diagnosis. Additional tests may include imaging studies of the brain and skeleton to assess damage from copper deficiency.

Treatment options

Copper replacement therapy with copper-histidine injections, most effective when started in the first weeks of life
Physical therapy to help with muscle tone and motor skill development
Occupational therapy to support daily living skills and developmental milestones
Seizure medications to control and prevent seizures
Feeding support including specialized formulas or feeding tubes if needed
Regular monitoring by a team of specialists including neurologists and geneticists
Temperature regulation support to prevent hypothermia
Bone health management to reduce fracture risk

Early treatment is essential for the best outcomes. While copper injections cannot reverse damage that has already occurred, they may slow disease progression when started very early. Families should work closely with medical specialists experienced in treating rare genetic disorders.

Frequently asked questions

The first signs usually appear between 6 weeks and 3 months of age. Parents may notice their baby has unusual hair that is sparse, colorless, or kinky. Other early signs include poor muscle tone, feeding difficulties, and failure to meet developmental milestones. Some infants may develop seizures or have difficulty maintaining normal body temperature.

Yes, Menkes disease can be detected through prenatal testing if there is a known family history. Genetic testing of cells from chorionic villus sampling or amniocentesis can identify ATP7A gene mutations. Prenatal diagnosis allows families to prepare for early treatment immediately after birth. Early copper replacement therapy may improve outcomes.

Menkes disease follows an X-linked recessive inheritance pattern. This means the mutated gene is located on the X chromosome. Males with one mutated copy will develop the disease, while females with one mutated copy are typically carriers without symptoms. Carrier mothers have a 50% chance of passing the mutation to each child.

Blood tests measuring copper and ceruloplasmin levels are key diagnostic tools. People with Menkes disease typically have very low levels of both markers. Ceruloplasmin is a protein that carries copper in the blood, and it requires copper to function properly. These blood tests should be followed by genetic testing to confirm the ATP7A gene mutation.

There is currently no cure for Menkes disease. However, early treatment with copper-histidine injections can help manage symptoms and slow disease progression. The most benefit occurs when treatment begins in the first few weeks of life, before significant neurological damage occurs. Supportive therapies help manage symptoms and improve quality of life.

Copper is essential for brain development and function. It helps form myelin, the protective coating around nerve cells. Without adequate copper, the brain experiences impaired neuron development, loss of myelin, and abnormal blood vessel formation. This leads to seizures, developmental delays, and progressive neurological decline in people with Menkes disease.

Copper is needed to produce enzymes that maintain healthy hair structure. Without enough copper, hair becomes weak, brittle, and twisted. The medical term for this distinctive hair is pili torti, meaning twisted hair. The hair often appears steel-colored or colorless and breaks very easily, making it one of the most recognizable signs of the condition.

Females rarely develop Menkes disease because they have two X chromosomes. Even if one carries the mutation, the other typically compensates. However, in very rare cases, females can show symptoms due to unfavorable X-chromosome inactivation or if they inherit two mutated copies. Most affected females are carriers who do not experience symptoms but can pass the mutation to their children.

Without treatment, most children with classical Menkes disease do not survive beyond early childhood, typically passing away by age 3. Early copper replacement therapy can extend life expectancy and improve quality of life. Some milder forms of the disease allow individuals to survive into their teenage years or beyond. Outcomes depend on the specific mutation and how early treatment begins.

Yes, siblings should be evaluated if a child is diagnosed with Menkes disease. Brothers have a 50% chance of inheriting the condition if their mother is a carrier. Sisters have a 50% chance of being carriers themselves. Genetic counseling and testing help families understand their risk and make informed decisions about family planning and early intervention if needed.